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Abstract
The ability of breast cancer cells to transiently transition between epithelial and mesenchymal 
states contributes to their metastatic potential. Therefore, driving tumor cells into a stable 
mesenchymal state, as opposed to complete tumor cell eradication, presents an opportunity to 
pharmacologically limit disease progression by promoting an asymptomatic state of dormancy. 
Here we compare a reversible model of epithelial-mesenchymal transition (EMT) induced by 
TGF-β to a stable mesenchymal phenotype induced by chronic exposure to the ErbB kinase 
inhibitor lapatinib. Only cells capable of returning to an epithelial phenotype resulted in skeletal 
metastasis. Gene expression analyses of the two mesenchymal states indicated similar transition 
expression profiles. A potently downregulated gene in both datasets was spleen tyrosine kinase 
(SYK). In contrast to this similar diminution in mRNA, kinome analyses using a peptide array and 
DNA-conjugated peptide substrates showed a robust increase in SYK activity upon TGF-β-
induced EMT only. SYK was present in cytoplasmic RNA processing depots known as P-bodies 
formed during the onset of EMT, and SYK activity was required for autophagy-mediated 
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clearance of P-bodies during mesenchymal-epithelial transition (MET). Genetic knockout of 
autophagy related 7 (ATG7) or pharmacological inhibition of SYK activity with fostamatib, a 
clinically approved inhibitor of SYK, prevented P-body clearance and MET, inhibiting metastatic 
tumor outgrowth. Overall, the current study suggests assessment of SYK activity as a biomarker 
for metastatic disease and the use of fostamatinib as a means to stabilize the latency of 
disseminated tumor cells.
Precis:
Findings present inhibition of spleen tyrosine kinase as a therapeutic option to limit breast cancer 
metastasis by promoting systemic tumor dormancy.
Introduction
Primary tumor metastasis is the culmination of several sequential processes including local 
and systemic invasion, dissemination and outgrowth within a secondary organ (1). 
Numerous studies have linked the process of epithelial-mesenchymal transition (EMT) to 
local invasion and dissemination (2). Additional studies also link EMT to the acquisition of a 
stem-like phenotype (3). However, separate studies indicate that tumor cells with a stable 
mesenchymal phenotype are less efficient at overcoming systemic dormancy and completing 
the last step of metastasis (4). Recently, we used a HER2 transformation model of human 
mammary epithelial cells (HME2) to establish stable and reversible states of EMT induced 
by lapatinib and TGF-β, respectively (5). Using this approach, we were able to establish that 
a cytokine-induced EMT is sufficient to facilitate resistance to lapatinib. Herein, we used 
these model systems to address the hypothesis that epithelial-mesenchymal plasticity (EMP) 
is required for metastasis. Moreover, we identify spleen tyrosine kinase (SYK) as a critical 
molecular mediator of EMP.
SYK is part of the EMT core signature of mRNAs down-regulated in mammary epithelial 
cells when EMT is induced by TGF-β, the expression of EMT-inducing transcription factors, 
or by the depletion of E-cadherin (6). There is also evidence that SYK can directly influence 
phenotypic transitions in epithelial cells. For example, depleting SYK in MCF10A 
mammary epithelial cells and in pancreatic carcinoma cells promotes morphologic and 
phenotypic changes characteristic of EMT (7,8). Finally, epithelial-derived cancer cells that 
bear a constitutive mesenchymal phenotype silence SYK expression via hypermethylation of 
its promoter (9). These studies suggest that SYK may serve as a tumor suppressor. However, 
expression values can be misleading, particularly with regard to kinases whose level of 
expression may not be consistent with the activity of the enzyme. Furthermore, even 
antibody-based protein analyses require robust expression of enzymes to obtain reliable 
readouts with regard to the activation state of a kinase. To overcome these drawbacks, we 
utilized direct enzymatic activity detection assays using a peptide substrate microarray. We 
also employed a phosphorylation assay in which a substrate peptide is conjugated to DNA 
oligonucleotides, whereby quantitative readouts of phosphorylation are achieved via qPCR. 
This method presents a highly sensitive and quantitative means to determine kinase activity 
within a sample (10)(11).
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To establish the mechanisms by which SYK modulates EMT, we have previously utilized a 
mass spectrometry approach to establish a list of substrate proteins (12). Among the 
substrates uniquely phosphorylated by SYK were several RNA-binding proteins. These 
included UPF1, LIMD1, EIF4ENIF1, CNOT2, LARP1, HNRNPK and DDX6. All of these 
proteins are known to localize in mRNA processing depots known as P-bodies (13,14). P-
bodies are dynamic cytoplasmic foci that contain mRNAs, microRNAs, and mRNA-binding 
proteins involved in translation repression, mRNA degradation, and microRNA-mediated 
silencing. We recently established that P-bodies form during the onset of EMT and are 
removed during mesenchymal-epithelial transition (MET) by the process of autophagy (15). 
Similar to EMT, the role of autophagy in tumorigenesis is dynamic and highly context 
dependent. However, recent studies indicate that autophagy is critical for cancer cells to 
overcome the stresses associated with several processes of metastasis, including survival 
during dormancy (16)(17).
Overall, our results strongly support the conclusion that EMP facilitates metastasis. We 
present DNA-conjugated peptide substrate assays as a highly sensitive, robust means to 
identify aggressive breast cancers. Using this approach, we establish that SYK activity is 
required for autophagy-mediated clearance of P-bodies during MET. Finally, our data 
indicates that pharmacological inhibition of SYK could serve as a unique therapeutic 
approach to limit the metastatic progression of breast cancer, not through tumor cell 
eradication, but maintenance of disseminated cells in an asymptomatic state of dormancy.
Materials and Methods
Cell lines and reagents
The HEK293 and 4T1 cells were obtained from the ATCC while the HMLE cells were a 
kind gift from Sendurai Mani (MD Anderson Cancer Center). The 4T1 and HMLE cells 
were constructed to stably express firefly luciferase and HMLE cells were transformed via 
overexpression of HER2 (HME2). Construction of the HME2 cells and their mesenchymal 
variants via treatment with TGF-β or Lapatinib were described previously (5,18). Normal 
murine mammary gland (NMuMG) cells were purchased from the ATCC. All cells were 
validated for lack of mycoplasma contamination using the IDEXX Cell check and Impact III 
testing on July 24th, 2018.
Immunological assays
For the co-immunoprecipitation assay, HEK293T cells stably expressing GST-SYK and 
EGFP-DCP1A were lysed as described above. EGFP-DCP1A was immunoprecipitated from 
the soluble fraction using GFP-Trap agarose beads (Chromotek). Bound immune complexes 
were washed with lysis buffer and subjected to immunoblotting using antibodies against 
GST and GFP. In separate experiments, whole cell lysates were analyzed by immunoblot 
using the following antibodies; pSYK, SYK, ATG7, Zo1, Zeb1, Slug (Cell Signaling 
Technologies), Actin (Santa Cruz Biotechnologies) or β-tubulin (DSHB). Where indicated, 
cells were harvested by tyrpsinization and stained with antibodies specific for CD44 and 
CD24 (Biolegend). Differential staining for these markers was analyzed by flow cytometry.
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RNA sequence analysis
Parental, HER2 transformed HMLE cells (HME2-parental), were treated every three days 
with TGF-β1 (5 ng/ml) or lapatinb (1 μM) for a period of 4 weeks to generate lapatinib 
resistant (LAPR) and post-TGF-β mesenchymal cell conditions (5). These cells were sorted 
for a CD44hi phenotype (BioLegend) and total RNA was isolated using E.Z.N.A (Omega 
Bio-Tek). RNA sequencing was conducted using the Illumina HiSeq 2500 platform. These 
data have been deposited on the GEO database (GSE115255).
Kinomic analyses
Lysates from HME2 cell conditions indicated above, were analyzed on tyrosine chip (PTK) 
and serine-threonine chip (STK) arrays using 15ug (PTK) or 2ug (STK) of input material as 
per standard protocol. Three replicates of chip-paired samples were used and 
phosphorylation data was collected over multiple computer controlled kinetic pumping 
cycles, and exposure times (0,10,20,50,100,200ms) for each of the phosphorylatable 
substrates. Slopes of exposure values were calculated, log2 transformed and used for 
comparison. Raw image analysis was conducted using Evolve2, with comparative analysis 
done in BioNavigator v6.2 (PamGene, The Netherlands).
qPCR-based kinase assays
A peptide substrate-oligonucleotide conjugate was prepared, as previously described (10). 
Briefly, a selective SYK peptide substrate derived from phage display selections (19) 
(SYKtide, EDPDYEWPSA) was purchased from GenScript on Rink amide polystyrene 
resin, and the N-terminus was acylated with 5-hexynoic acid. Peptide was cleaved from resin 
by incubating in a cleavage cocktail (95:2.5:2.5 TFA:H2O:TIPS) for 4 hours followed by a 
precipitation in cold ether. The resulting precipitate was subsequently purified by semi-prep 
HPLC at a flow rate of 5mL/min with H2O (0.1% TFA) and MeCN (0.1% TFA) as mobile 
phase. The peptide was characterized by MALDI/MS. m/z: [M+H]+ calcd. for 
C60H77N12O21+, 1301.53, found [M+Na]+, 1323.35, [M+K]+, 1339.32.
The SYKtide alkyne was conjugated to a 20-mer DNA oligo 
(ATGGTATCAAGCTTGCCACA) containing a 5’ azide modification, as described (11). 
The resulting conjugate was precipitated by adding 100μL of 10M ammonium acetate and 
800μL of EtOH and being kept in −20°C overnight. After removal of supernatants, the 
resulting conjugate was purified by semi-prep HPLC at a flow rate of 1mL/min with H2O 
(0.75% hexafluoroisopropanol (HFIP), 0.75% triethylamine (TEA), 5μM EDTA, pH 7.0) 
and 10:90 H2O:MeOH (0.75% HFIP, 0.75%TEA, 5μM EDTA, pH 7.0) as mobile phase. The 
resulting conjugate was characterized by ESI/MS. m/z: [M-5H]5−, calcd. 1600.6, found 
1600.7, [M-6H]6−, calcd. 1333.7, found 1333.7, [M-7H]7−, calcd. 1143.0, found 1142.8, 
[M-8H]8−, calcd. 1000.0, found 1000.0, [M-9H]9−, calcd. 888.8, found 888.8, [M-10H]10−, 
calcd. 799.8, found 799.8, [M-11H]11−, calcd. 727.0, found 727.0, [M-12H]12−, calcd. 
666.3, found 666.3, [M-13H]13−, calcd. 615.0, found 615.0.
MPER lysis buffer (Thermo Scientific 78501) was prepared with protease and phosphatase 
inhibitors (Protease Inhibitor Cocktail 1, Sigma #P8340, Phosphatase Inhibitor Cocktail 2, 
Sigma #P5726, and Phosphatase Inhibitor Cocktail 3, Sigma #P0044) at 1:100 concentration 
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each in our sample preparation. HME2 cell derivates (1 million cells each) were harvested, 
treated with lysis buffer (500 μL) to each cell pellet, and incubated on ice for 30 minutes. 
Cell lysate was obtained by centrifugation for 10 minutes at 4 °C at 14,000 g. The protein 
concentration was quantified using BCA protein assay solution (Thermo scientific).
Kinase activity reactions were performed in 50 mM Tris-HCl pH 7.5 and 10 mM MgCl2), 1 
mM ATP, 2 mM DTT, 1 μM phagetide-DNA conjugate (20-mer DNA oligo), and 1 μg total 
protein from cell lysates. Reactions were performed at room temperature for 30 minutes, and 
then enzymes were heat denatured by treatment at 65 °C for 5 minutes. After cooling to 
room temperature, encoding 55-mers were allowed to anneal for 30 minutes, as described 
(11). Selective purification of DNAs bearing phosphorylated peptides was performed using 
anti-photyrosine antibody (4G10, EMD Millipore) immobilized on protein G magnetic 
beads (protein G magnetic Sepharose, GE Healthcare). qPCR was used to quantitate 
encoding 55-mers in both the pre-sample (before pull-down by antibody) and post-sample 
(after elution with 1 mM phenyl phosphate from antibody-protein G beads).
Gene knockout studies
The dimeric CRISPR RNA-guided Fokl nuclease and Csy4-based multiplex gRNA 
expression system was used to generate the SYK and ATG7 knockout cell lines. Two 
annealed target-site oligoduplexes designed by Zifit Targeter (20) and a constant region 
oligoduplex were assembled with BsmBI-digested pSQT1313 in a single-step ligation. 3 μg 
of the ligated vector, 1 μg of pSQT1601 expressing Csy4 RNase and RNA-guided Fokl-
dCas9 fusion nucleases, and 0.2 μg of pBABE Puro were transfected into luciferase-
expressing HME2 and 4T1 cells. pSQT1313 and pSQT1601 were gifts from Keith Joung 
(Addgene plasmids #53370 and #53369) (21). After 48 hours, cells were treated with 5 
μg/ml puromycin for clonal selection. Genomic DNA and cell lysates from selected colonies 
were analyzed by the PAGE-genotyping method (22) and immunoblot analyses to screen for 
clones with SYK or ATG7 knockout. Disruption of both alleles was confirmed by DNA 
sequencing.
P-body formation and clearance
Cells were treated with TGF-β1 (R&D Systems) (10 ng/ml) for the indicated times to induce 
P-bodies. For P-body clearance assays, cells were washed with phosphate-buffered saline 
(PBS) and then allowed to recover in fresh media for the indicated times. In some 
experiments, the SYK inhibitor R406 (Selleckchem), or the autophagy inhibitors N2,N4-
bis(phenylmethyl)-2,4-quinazolinediamine (DBeQ) (Sigma; 0.625–2.5 μM) or chloroquine 
(Tocris; 10 μM) were added during P-body clearance. For the detection of P-bodies and 
autophagosomes by immunofluorescence, cells were fixed with 10% ice cold methanol for 
10 min, permeabilized with 1% Triton X-100 in PBS, and blocked with PBS containing 10% 
goat serum, 0.05% Tween 20, and 1 mg/ml BSA. Cells were immunostained using the 
indicated antibodies against DCP1A, p62, or phosphotyrosine. Bound primary antibodies 
were detected using AlexaFluor 488-conjugated goat anti-mouse IgG and/or AlexaFluor 
594-conjugated goat anti-rabbit IgG secondary antibodies (Invitrogen). P-bodies were 
quantified using ImageJ to set a threshold mask (Otsu Thresholding Filter), which allowed 
only P-bodies (puncta) to be analyzed. The pixel range of P-bodies were set at a range 
Shinde et al. Page 5
Cancer Res. Author manuscript; available in PMC 2020 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
between 30 and 270 units. This range was considered to have staining above background. 
The number of P-bodies and nuclei were counted in an image or field containing at least 25 
cells to determine the number of P-bodies per cell. Data are expressed as the mean ± 
standard error of the mean (SEM) from 3 independent biological replicates.
In vivo metastasis
Control and ATG7-deleted 4T1 cells engineered to express firefly luciferase were 
resuspended in PBS (50 μl) and orthotopically engrafted onto the second mammary fat pad 
of 4 week old Balb/c mice (2.5×104 cells/mouse) (Jackson Labs, Bar Harbor, ME). Primary 
tumor growth and metastasis development were assessed via weekly bioluminescent 
imaging using the Advanced Molecular Imager (AMI) (Spectral Instruments, Tucson, AZ). 
In separate experiments, 4T1 primary tumors were engrafted onto Balb/c and NRG mice and 
primary tumors were surgically excised when they reached 200mm3. At this point mice were 
split into cohorts at treated with fostamatinib (50 mg/kg; p.o./q.d.). Upon necropsy lungs 
from all animals were removed and fixed in 10% formalin and dehydrated in 70% ethanol 
for visualization of pulmonary metastatic nodules and histological analyses. All animal 
studies were performed in accordance with the animal protocol procedures approved by the 
Institutional Animal Care and Use Committee (IACUC) of Purdue University.
EMT score quantification
EMT metric previously described was applied to calculate EMT scores for various samples 
(23). A set of EMT-relevant predictors and cross-platform normalizer transcripts was 
extracted for each sample and then used to assign probabilities of belonging to E, hybrid 
E/M, or M phenotypes, as denoted by the ordered triple Si = (PE, PE/M, PM). Categorization 
was assigned based on maximal value of this ordered triple, and then projected onto [0, 2].
Statistical analyses
2-way ANOVA or 2-sided T-tests were used where the data met the assumptions of these 
tests and the variance was similar between the two groups being compared. P values of less 
than 0.05 were considered significant. No exclusion criteria were utilized in these studies.
Results
Epithelial-mesenchymal plasticity is drives metastasis
We recently established two mesenchymal cell conditions derived from a common, HER2-
transformed, human mammary epithelial cell (HME2) precursor (5). In one condition, EMT 
was induced upon prolonged continuous treatment (4 weeks) with the cytokine TGF-β1 and 
the other was induced upon a similar length of continuous treatment with the EGFR/HER2 
kinase inhibitor, lapatinib. Importantly, while both mesenchymal states are robust, only 
TGF-β-induced EMT was capable of undergoing MET upon withdrawal of the exogenous 
stimuli (5). The resultant cell populations are illustrated in Figure 1a via flow cytometric 
analysis of CD44 and CD24, where treatment and withdrawal of TGF-β1 resulted in the 
formation of a heterogeneous population of epithelial and mesenchymal cells (Fig 1a). In 
contrast, lapatinib resistant cells (LAPR) derived from prolonged treatment with the kinase 
inhibitor remained in a mesenchymal, CD44hi phenotype even after prolonged withdrawal of 
Shinde et al. Page 6
Cancer Res. Author manuscript; available in PMC 2020 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the compound. We sought to evaluate the impact of these reversible versus stable EMT 
events on tumor growth and metastasis. Therefore, we co-engrafted the LAPR cells with the 
parental HME2 cells to create CD44hi / CD44low heterogeneous tumors, similar to the post-
TGF-β1 population. The mixture of LAPR cells with parental HME2 cells did not affect 
primary tumor growth and we did not observe any metastasis in mice bearing either of these 
tumors (Fig 1b-1d). In contrast, the post-TGFβ1 treated cells formed larger tumors and we 
were able to image and isolate metastases within the long bones of one of these tumor 
bearing mice (Fig 1b-1d). Ex-vivo subculture of these bone metastases (HME2-BM) led to a 
culture that displayed a uniform epithelial morphology similar to that of the HME2 parental 
cells but with diminished cell surface expression of CD24 (Fig 1d-1e). Taken together, these 
data indicate that EMP is critical for the metastatic progression of this HER2 transformation 
model.
Reversible and irreversible EMT’s have similar transition intensities
We next sought to characterize unique differences in gene expression between reversible and 
irreversible EMT events induced by TGF-β and kinase inhibition, respectively. Following 4 
weeks of treatment with TGF-β1 or lapatinib, CD44hi cells were sorted by FACS and 
analyzed by RNA sequencing. Both of these cell populations were compared to non-
stimulated, parental HME2 cells. Numerous established markers of EMT such CDH1, 
Vimentin, Twist, and FGFR1 were similarly modulated by both TGF-β1 and lapatinib 
treatment (Fig 2a). Only a limited set of genes were uniquely regulated between TGF-β and 
lapatinib-induced EMT events (Fig 2b). Pathway analysis of these gene sets did not offer 
obvious mechanistic explanation for these reversible versus non-reversible EMT events (Fig 
2b; Supplementary Table 1). To investigate the notion that EMT becomes irreversible based 
on the intensity of an EMT, we utilized our recently developed inferential model of 
quantifying the extent of EMT in a given sample (23). This metric uses canonical epithelial 
and mesenchymal markers to compute the ‘EMT score’ on a scale of 0 (fully epithelial) to 2 
(fully mesenchymal). These analyses indicated that both TGF-β1 and lapatinib induced 
similar EMT intensities (Fig 2c). These analyses suggest that the reversible nature of EMT is 
determined via the nature of the inducing stimuli as opposed to the intensity of the 
transition.
SYK activity is increased upon TGF-β-induced EMT
To further characterize post-transcriptional differences that may be regulating EMP, we 
conducted an analysis of kinase activity using a peptide-substrate microarray on the 
PamStation-12 platform. This platform is capable of quantifying the differential 
phosphorylation of 142 serine/threonine containing peptides and 140 different tyrosine 
containing peptides upon incubation with cell lysates. This analysis detected an moderate 
decrease in phosphorylation of a peptide containing the autophosphorylation sites found 
within the activation loop of SYK, containing tyrosine 525 and 526 (Supplementary Table 2; 
(24)). However, consistent with previous studies, we observed SYK mRNA expression to be 
drastically downregulated upon treatment with TGF-β (6). Moreover, use of the KM plotter 
analysis tool indicated that diminished SYK mRNA expression is strongly associated with 
decreased breast cancer patient survival (Fig 3a; (25)). Therefore, we normalized the peptide 
phosphorylation values to SYK mRNA expression reads from our RNA sequence analyses. 
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Use of this approach clearly demonstrated that, while SYK expression was downregulated 
by TGF-β-induced EMT, the activity of the remaining pool was dramatically increased (Fig 
3b). Consistent with our RNA sequence analyses, immunoblotting of whole cell lysates 
demonstrated a robust decrease in the total levels of SYK in TGF-β-treated and Lapatinib-
resistant cells (Fig 3c). Differential phosphorylation of Y525/526 of endogenous SYK was 
not detectable in any of these samples, potentially due to the dramatic reduction in total 
SYK during EMT (Fig 3c, Supplementary Fig 1). Therefore, to verify enhanced SYK 
activity following TGF-β-induced EMT, we conducted a substrate phosphorylation assay 
using SYK PhageTIDE, a peptide sequence (EDPDYEQPSA) identified by phage display to 
be a highly specific and sensitive substrate for SYK as compared to the Y525/526 containing 
activation loop autophosphorylation peptide (19,26). This peptide was conjugated to a DNA 
oligonucleotide, allowing for highly sensitive quantification of phosphorylated peptide via 
PCR following its capture using the antityrosine antibody 4G10. Using this ultrasensitive 
approach, we were able to clearly demonstrate enhanced SYK activity specifically in HME2 
cells induced to undergo EMT by TGF-β as compared to Lapatinib-induced EMT (Fig 3d). 
Taken together these data clearly indicate that in contrast to diminished total expression 
levels of SYK, its kinase activity was upregulated in a reversible, but not an irreversible 
EMT.
SYK is present in P-bodies and facilitates their clearance during MET
We have recently demonstrated that induction of EMT by TGF-β induces the formation of 
cytoplasmic RNA processing complexes called P-bodies, and clearance of P-bodies through 
autophagy is required for reversal of EMT (15). Based on our previous identification of a 
role for SYK in promoting stress granule clearance through autophagy and our identification 
of multiple P-body proteins as SYK substrates, we next sought to assess a role for SYK in P-
body formation and clearance (27)(11). Expression of mCherry labeled SYK results in a 
cellular diffuse localization (Fig 4a). However, coexpression of the P-body structural protein, 
DCP1A leads to formation of large P-bodies and SYK clearly concentrated into these 
structures (Fig 4a). This dramatic change in SYK localization occurred in 100% of cells 
containing P-bodies (Supplementary figure 2). Despite the relative insolubility of P-body 
complexes, we were able to use immunoprecipitation to demonstrate association of EGFP-
DCP1A with a GST tagged SYK (Fig 4b). Consistent with SYK activity within P-bodies, we 
observed a dramatic increase in phosphotyrosine staining in P-bodies selectively within cells 
overexpressing SYK (Fig 4c). Normal murine mammary gland (NMuMG) cells are highly 
responsive to TGF-β-induced EMT, and form robust P-bodies during this process (15). 
Therefore, we treated control and SYK overexpressing NMuMG cells with TGF-β1 for 48 
hours to induce P-body formation. At this point the TGF-β was removed and cells were 
placed in fresh media for an additional 24 hours to allow for P-body clearance. The 
induction of P-bodies was not affected by SYK overexpression, but the clearance of P-
bodies after TGF-β removal was significantly increased (Fig. 4d and 4e). This SYK-
mediated clearance of the P-bodies was prevented by inhibition of autophagy through 
blockade of endosomal acidification using the antimalarial drug, chloroquine, during the 
recovery period following TGF-β-induced EMT (Fig 4f). Taken together, these data are 
consistent with a model in which SYK physically concentrates into P-bodies upon TGF-β-
induced EMT and functions to promote their autophagic clearance during MET.
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SYK activity is required for mesenchymal-epithelial transition
To determine the necessity of SYK in the ability of cells to undergo EMT and MET we 
deleted SYK from the HME2 cells using a genome editing approach (Fig 5a; (15)). 
Complete absence of SYK led to an accumulation of P-bodies and prevented P-body 
clearance following TGF-β-induced EMT (Fig 5b-c). To focus on the role of SYK kinase 
activity in P-body clearance and execution of the MET process we treated cells with TGF-β 
and allowed them to recover in the absence or presence of the SYK inhibitor R406. 
Association of p62/Sequestosome-1 with LC3 targets these proteins to autophagosomes 
where they are degraded selectively through autophagy. Similar to DCP1A, when autophagy 
is inhibited p62-positive inclusion bodies accumulate (28,29). Consistent with a role of SYK 
activity in autophagy-mediated clearance of P-bodies, we observed robust accumulation of 
p62 and DCP1A containing vesicles when R406 was included during recovery from TGF-β 
treatment (Fig 5d). Following a 4-week treatment of the HME2 cells with TGF-β1 a 2-week 
recovery period allowed levels of Epithelial-cadherin (Ecad) to return (Fig 5e). When R406 
was added during the recovery phase, however, return of Ecad was attenuated (Fig 5e). 
Consistent with our previous report (14), addition of the autophagy inhibitor DBeQ similarly 
prevented cells from undergoing MET subsequent to TGF-β1 treatment and withdrawal 
(Supplementary figure 3). The onset of TGF-β1-induced EMT can easily be visualized via 
bright field microscopy with all cells displaying a mesenchymal morphology (Fig. 5f). This 
was also quantified by a CD44hi flow cytometric phenotype (Fig 5g). This approach clearly 
indicated that R406 prevents the ability of cells to undergo MET following TGF-β1-induced 
EMT (Fig 5e-5g). These results suggest that SYK activity facilitates autophagy-mediated P-
body clearance during MET.
Inhibition of autophagy stabilizes a mesenchymal phenotype and inhibits metastasis
Using an in vivo reporter system, we have previously established that highly metastatic 4T1 
cells are very dynamic and undergo EMT and MET during initiation of growth in 3D culture 
and during in vivo tumor formation and metastasis (30,31). To establish the necessity of 
autophagy-mediated MET for metastasis, we again utilized a genomic editing approach to 
delete the autophagy mediator, ATG7 (Fig 6a). Consistent with the dynamic EMP phenotype 
of the 4T1 cells and the requirement of autophagy for MET, deletion of ATG7 led to 
stabilization of a mesenchymal phenotype that included the accumulation of P-bodies (Fig 
6a and 6b; Supplementary fig 4). Correspondingly, deletion of ATG7 prevented efficient 
growth within a compliant 3D culture environment (Fig 6c). Deletion of ATG7 had a 
minimal effect on primary tumor growth within the mammary fat pad (Fig 6d). 
Histologically, ATG7 deleted tumors displayed a similar mesenchymal morphology, 
characteristic of 4T1 primary tumors, and cell proliferation was not affected (Fig 6e). In 
contrast, deletion of ATG7 led to a complete inhibition of pulmonary metastasis as measured 
by longitudinal bioluminescence and endpoint enumeration of metastatic nodules (Fig 
6f-6h). Taken together these data strongly suggest that highly metastatic cells consistently 
transition between epithelial and mesenchymal phenotypes, and autophagy is required for 
the efficient execution of MET and metastatic progression.
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Pharmacological inhibition of SYK stabilizes a mesenchymal morphology and inhibits 
metastatic outgrowth
Consistent with our ATG7 genetic data, previous studies indicate that inhibition of 
autophagy, through the use of chloroquine, effectively inhibits the pulmonary metastasis of 
4T1 tumors (32). In attempts to improve the pharmacological specificity of targeting 
autophagy as an anti-metastatic therapy, we sought to evaluate the impact of SYK inhibition 
in the 4T1 model. In vitro, treatment of 4T1 cells with R406 stabilized a mesenchymal 
morphology, and potently inhibited tumor cell growth in 3D culture conditions (Fig 7a and 
7b). We next conducted in vivo studies using the clinically approved pro-drug of R406, 
fostamatinib (33). To specifically focus on inhibition of metastasis, we established primary 
mammary fat pad tumors for a period of 2 weeks, and only after surgical resection of these 
primary tumors were mice treated with fostamatinib (Fig 7c). This approach confirmed that 
systemic inhibition of SYK is capable of inhibiting the pulmonary metastatic outgrowth of 
4T1 cells (Fig 7d and 7f). Consistent with a role of SYK in MET, micrometastases that were 
located in the fostamatinib-treated group failed to regain Ecad expression as compared to 
similar sized lesions in untreated animals (Fig 7g).
Discussion
Transient suppression of a differentiated epithelial phenotype by breast cancer cells is 
strongly associated with an increased invasive phenotype and perpetuation of the early steps 
of metastasis (34). Mesenchymal cells also have an increased capacity to persist in the 
presence of chemotherapy (4,35,36). Our previous studies and our data herein are consistent 
with the notion that autophagy drives the MET process and efficient progression to 
macroscopic tumor formation (15). Our findings are strongly supported by recent studies 
indicating autophagy facilitates a dormant-to-proliferative switch by tumors cells within the 
lungs (16). Therefore, autophagy is intimately linked to the plasticity of tumor cells to 
transition between epithelial and mesenchymal states, processes that are critical for 
dissemination, drug resistance and metastatic outgrowth.
In addition to chemotherapy numerous studies indicate that when cells transition into a 
mesenchymal state they also become highly resistant to kinase inhibitors, antibody therapies, 
and even immunotherapy (37)(38)(39). Therefore, the goal of complete eradication of these 
dormant, highly drug resistant subpopulations may be unattainable. Herein, we explored 
approaches to pharmacologically maintain populations of disseminated cells in an 
asymptomatic state by preventing their reversion back to an epithelial state. By combined 
genetic and kinase activity analyses, we were able to identify SYK as being strongly 
activated in mesenchymal cells that are capable of reverting back to an epithelial phenotype 
and giving rise to lung and long bone metastases. The role of SYK in this process is to 
promote the removal of P-bodies through autophagy, an event that supports MET following 
initiation of metastatic outgrowth.
Our findings also emphasize the importance of properly interpreting data within publicly 
available databases that are largely based on mRNA and protein expression values (40,41)
(42). There are examples, such as HER2, where enhanced expression of kinases drives their 
auto activation and predicts for sensitivity to inhibitors. The corollary, however, is not well 
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established. Indeed, mRNA expression analyses demonstrate a strong correlation between 
decreased SYK expression and improved patient survival, suggesting it functions as a tumor 
suppressor (8). However, our data clearly indicate that although SYK expression is 
dramatically inhibited with TGF-β, its activity is increased on a per-molecule level and it is 
spatially concentrated into P-bodies. The mechanisms of SYK activation and translocation to 
P-bodies, following TGF-β-induced EMT are yet to be established and are currently under 
investigation in our laboratory. However, the presence of high levels of phosphotyrosine in 
P-bodies and stress granules (27), suggests that SYK associates with ribonucleoprotein 
particles when it is in an activated state.
We also suggest the diagnostic utility of substrate kinase assays to overcome the pitfalls of 
gene expression analyses. Our oligonucleotide-peptide conjugate approach offers an 
extremely sensitive method to quantify kinase activity. The approach herein utilized a single 
peptide substrate optimized for SYK specificity (19). However, our qPCR-based readout 
presents the opportunity to utilize oligonucleotides with unique bar codes flanked by shared 
priming sequences linked to a variety of substrate-specific peptides, which is the subject of a 
forthcoming manuscript. This approach will allow for quantitative readouts of multiple 
kinase substrates all within a single reaction (11). Clearly, this type of enzymatic activity-
based diagnostic that can be conducted in a single reaction on small amounts of tissue holds 
great promise for predicting personalized cancer therapeutics.
SYK is well established as a key signaling molecule in B-cell activation. As such, 
fostamatinib was developed and has shown clinical efficacy for the treatment of B-cell 
associated diseases such as rheumatoid arthritis and lymphoma (24,43). Furthermore, 
fostamatinib was recently approved for the treatment of chronic immune thrombocytopenia 
(ITP). Our data suggest repurposing of fostamatinib as an effective treatment for the 
prevention of metastatic recurrence in breast cancer. The clinical trial parameters for this 
type of recurrence prevention strategy are difficult. However, fostamatinib might be 
particularly suited for this approach given it was developed as a long-term therapeutic for 
treatment of a chronic disease and thus has a very low toxicity profile (44,45). In addition to 
the tumor cell autonomous effects presented herein, systemic treatment with fostamatinib 
also prevents B-cell-mediated promotion of a protumorigenic microenvironment (46,47). 
Understanding this potential polypharmacology upon systemic treatment with fostamatinib 
clearly warrants further investigation.
Overall, the current studies have utilized a variety of genetic, proteomic and 
pharmacological techniques to demonstrate that SYK activity and ATG7-mediated 
autophagy are required for MET, the vital final step in formation of macroscopic metastases. 
More broadly, our work also highlights an exit from the traditional pharmacological goal of 
total tumor cell eradication and instead posits the concept of forced tumor dormancy for the 
management of stage IV breast cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Epithelial-mesenchymal plasticity is required for metastasis.
(A) HER2 transformed HMLE cells (HME2) were treated with TGF-β1 (5 ng/ml every three 
days) or the HER2/EGFR kinase inhibitor lapatinib (1 μM every three days) for 4 weeks. 
Following an additional 4 weeks of culture in the absence of these stimuli the post-TGF-β 
and lapatinib resistant (LAPR) cells were analyzed by flow cytometry for expression of 
CD44 and CD24. Untreated (Parental) cells served as a control. (B and C) The cell 
populations shown in panel A were engrafted onto the mammary fat pad of NSG mice and 
primary tumor size was measured by digital calipers at the indicated time points. Primary 
tumor weights were measured 30 days after engraftment following surgical resection. Data 
in B and C are the mean ±SD of three mice per group, resulting in the indicated P values. 
(D) Forty-five days after removal of the primary tumor, long bone metastases were detected 
in a post-TGF-β tumor bearing mouse. These metastases were subcultured to yield the 
HME2-bone metastatic (HME2-BM) cell line. (E) The HME2-BM cells were characterized 
via flow cytometric analysis of CD44 and CD24.
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Figure 2. Reversible and irreversible EMT’s have similar transition intensities.
(A) Heat map representation of the differentially expressed genes determined by RNA-
sequence analyses of parental HME2 cells (Par) as compared to HME2 cells treated with 
TGF-β1 (5ng/ml every 3 days for 4 weeks) and those selected for resistance to lapatinib 
(LAPR; 1μM every 3 days for 4 weeks). (B) Principle component analyses of the duplicate 
gene expression analyses described in panel A. (C) EMT score analysis of differential gene 
expression for the indicated cell populations.
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Figure 3. Spleen tyrosine kinase activity is specifically increased following TGF-β-induced EMT.
(A) Kaplan Meier analysis of recurrence free survival based on the median expression value 
of SYK. Data were obtained from the indicated patient numbers, using the KM plotter 
online analysis tool, resulting the indicated P value. (B) Substrate phosphorylation intensity 
determined for a peptide containing the SYK autophosphorylation (Y525/Y526) site in 
HME2 parental, lapatinib resistant (LAPR) and TGF-β treated cells. Data are normalized to 
SYK mRNA expression values determined by RNA sequence analysis for these same 
samples. Data are mean ±SD of three substrate phosphorylation analyses resulting in the 
indicated P value. (C) Immunoblot analysis of total SYK in HME2 parental, lapatinib 
resistant (LAPR) and TGF-β treated cells. β-tubulin was assessed as a loading control. (D) 
Quantification of SYK activity in the indicated cell populations using a DNA-conjugated 
SYK specific substrate peptide (SYK-PhageTIDE). Data are mean ±SD of the signal for 
three unique 55-mer encoding constructs in a lysate sample resulting in the indicated P 
values.
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Figure 4. SYK enhances the clearance of TGF-β-induced P-bodies.
(A) HEK293 cells were transiently transfected with SYK-mCherry (SYK-mC) and EGFP as 
a control or EGFP-DCP1A to induce P-body formation. Localization of SYK into P-bodies 
was examined by fluorescence microscopy. (B) HEK293 cells expressing GST-SYK were 
transiently transfected to express EGFP-DCP1A, which was immunoprecipitated from cell 
lysates using GFP-Trap agarose beads. Proteins in immune complexes (Anti-GFP) and the 
cell lysate were detected using antibodies against GST (GST-SYK) and EGFP (EGFP-
DCP1A). (C) Control and SYK-mCherry (SYK-mC) expressing HEK293 cells were 
transiently transfected with EGFP-DCP1A to induce P-bodies. After transfection, the cells 
were stained using antibodies against phosphotyrosine (P-Tyr) and cells were examined by 
fluorescence confocal microscopy to visualize colocalization of SYK, DCP1A and P-Tyr. 
(D) Control NMuMG cells and those stably expressing SYK-mC were left untreated 
(Control) or treated with TGF-β1 for 48 hours. Where indicated, cells were allowed to 
recover in the absence of TGF-β (Recovery) for and additional 24 hours. Cells were fixed 
and stained for DCP1A (green). (E) Quantification of the average number of P-bodies per 
cell ± SEM (n > 150 cells per treatment) for triplicate experiments resulting in the indicated 
P value. (F) NMuMG cells stably expressing SYK-mC were treated with TGF-β1 and 
allowed to recover as in panel D. Where indicated the autophagy inhibitor chloroquine was 
added during the recovery period and cells were fixed and stained for DCP1A (green). P-
bodies were quantified as above resulting in the indicated P value.
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Figure 5. Inhibition of the SYK activity prevents MET.
(A) Genetic knockout of SYK (SYK KO) in the HME2 cells was verified by immunoblot. 
Tubulin (TUB) served as a loading control. (B) These cells were stimulated with TGF-β1 for 
17 days. Where indicated, cells were allowed to recover in the absence of TGF-β 
(Recovery) for and additional 96 hours. Cells were fixed and stained for DCP1A (green). (C) 
Quantification of the average number of P-bodies per cell. Data are the mean manual 
analyses of P-bodies ±SEM of at least 10 cells resulting in the indicated P values. (D) 
HMLE cells were treated with TGF-β for 96 hours to induce P-body formation. Cells were 
allowed to recover for 48 hours in the absence (Control) or presence of the SYK inhibitor 
R406 (2.5 μM). Cells were fixed and stained with antibodies against DCP1A (green) and the 
autophagy marker p62 (red). Nuclei were counterstained with DAPI (blue). (E) HME2 cells 
were treated with TGF-β1 (5 ng/ml every 3 days for 4 weeks) and subsequently allowed to 
recovery for an additional 2 weeks in the absence or presence of the R406 (1.0 μM). These 
cells as well as untreated HME2 cells (Cntrl) were analyzed for the expression of the 
epithelial cadherin (Ecad). Expression of Actin served as a loading control. (F) HME2 cells 
were left untreated (Control) or treated and allowed to recovery from TGF-β1 stimulation as 
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described in panel E. The epithelial and mesenchymal morphologies under these conditions 
were visualized by phase contrast microscopy. The yellow outline denotes the return of 
morphologically epithelial cells following treatment and recovery from TGF-β1. (G) HME2 
cells were treated as in panel B and analyzed by flow cytometry for cell surface expression 
of CD24 and CD44.
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Figure 6. Autophagy is required for MET and metastasis.
(A) Genetic knockout of ATG7 (ATG7KO) in the 4T1 cells was verified by immunoblot. 
These same cell lysates were also analyzed for the EMT markers, Zo1, Zeb1 and Slug. 
Expression of Actin served as a loading control. (B) Control (WT) and ATG7KO 4T1 cells 
were stained with phalloidin to visualize differential organization of the actin cytoskeleton 
and DCP1A to visualize P-bodies. These cells were counterstained with DAPI to visualize 
the nucleus. (C) Control (WT) and ATG7KO 4T1 cells were grown under single cell 3D 
culture conditions. Longitudinal cellular outgrowth was quantified by bioluminescence at the 
indicated time points. Data are normalized to the plated values and are the mean ±SD of 
three independent analyses resulting in the indicated P-value. (D) Control (WT) and 
ATG7KO 4T1 cells were engrafted onto the mammary fat pad and primary tumor growth 
was quantified by bioluminescence at the indicated time points. Data are normalized the 
injected values. (E) Immunohistochemistry for Ki67 expression in control (WT) and 
ATG7KO primary tumors. (F) Bioluminescent images and the corresponding gross 
anatomical views of lungs from control 4T1 (WT) tumor bearing mice and those bearing 
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ATG7KO tumors. Arrows indicate metastatic nodules. (G) Quantification of bioluminescent 
radiance from the pulmonary region of WT and ATG7KO tumor bearing mice at the 
indicated time points. (H) Upon necropsy the numbers of pulmonary metastatic nodules 
were quantified for both control (WT) and ATG7KO 4T1 tumor bearing mice. For panels D, 
G, and H, data are the mean ±SE of 5 mice resulting in the indicated P values.
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Figure 7. Inhibition of SYK stabilizes a mesenchymal phenotype and inhibits pulmonary 
metastatic outgrowth.
(A) 4T1 cells were treated with R406 (1 μM) for 18 days, fixed and stained with phalloidin 
(red) to visualize redistribution of the actin cytoskeleton and antibodies against DCP1A 
(green) to visualize P-body formation. Nuclei (blue) were counterstained with DAPI. (B) 
4T1 cells were placed under single cell 3D culture conditions in the absence (DMSO) or 
presence of R406 (1 μM) and cellular outgrowth within these cultures was quantified by 
bioluminescence at the indicated time points. Data are the mean ±SE of two independent 
assays completed in triplicate, resulting the in the indicated P value. (C) Schematic 
representation of the experimental approach. 4T1 primary tumors were established and 
surgically resected. Following this procedure mice were treated with fostamatinib (50mg/kg; 
PO qd). (D) Representative BLI images of mice treated as described in panel C. (E) 
Pulmonary radiance values for control (DMSO) and fostamatinib treated mice at the 
indicated time points. (F) Upon necropsy macroscopic pulmonary metastasis were 
enumerated in lungs of control (DMSO) and fostamatinib treated mice. Data in panels E and 
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F are the mean ±SE of five mice per group resulting in the indicated P values. (G) 
Histological sections of similar sized 4T1-metastases in control (DMSO) and fostamatinib-
treated groups. Sections were stained with H&E or antibodies against Ecad.
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